Indeed, serum EPA levels are related to the effect of dipeptidyl-peptidase IV (DPP-4) inhibitor, which decreases blood glucose levels through increasing circulating GLP-1 levels, in Japanese patients with type 2 diabetes [24]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.